Transplant and autoimmune immunosuppressants

Transplant and autoimmune immunosuppressants

Drug monograph · NCLEX study reference
Trade names	Neoral, Sandimmune, Prograf, CellCept, Imuran, Rapamune, Simulect
Therapeutic class	Immunosuppressant
Pharmacologic class	Calcineurin inhibitors (cyclosporine, tacrolimus), antiproliferative (mycophenolate, azathioprine), mTOR inhibitor (sirolimus), monoclonal antibody (basiliximab)
Onset / peak / duration	Chronic therapy; basiliximab given around transplant.
Half-life / level	Cyclosporine and tacrolimus and sirolimus are monitored by trough levels (narrow therapeutic range).
Routes	PO (oral), IV
High-alert (ISMP)	No
Black box warning	Yes (see Safety)
Antidote / reversal	Supportive care; hold and adjust.
Pregnancy / lactation	Mycophenolate contraindicated; others under specialist care.

Nursing pharmacology study reference (NCLEX-style monograph). Numeric values are standard teaching ranges for study and must be verified against current manufacturer labeling before clinical use. This is educational content, not prescribing guidance.

Transplant and autoimmune immunosuppressants (brand names Neoral, Sandimmune, Prograf, CellCept, Imuran, Rapamune, Simulect) — Immunosuppressant; Calcineurin inhibitors (cyclosporine, tacrolimus), antiproliferative (mycophenolate, azathioprine), mTOR inhibitor (sirolimus), monoclonal antibody (basiliximab).

Identification

• Therapeutic class: Immunosuppressant.
• Pharmacologic class: Calcineurin inhibitors (cyclosporine, tacrolimus), antiproliferative (mycophenolate, azathioprine), mTOR inhibitor (sirolimus), monoclonal antibody (basiliximab).

Pharmacology

• Mechanism of action: Suppress T-cell or lymphocyte activity to prevent transplant rejection and treat autoimmune disease.
• Onset / peak / duration: Chronic therapy; basiliximab given around transplant.
• Half-life / therapeutic level: Cyclosporine and tacrolimus and sirolimus are monitored by trough levels (narrow therapeutic range).

Clinical use

• Indications: Prevention of organ transplant rejection, severe autoimmune disease.
• Usual dose, route, frequency: PO or IV, dosed to trough levels; basiliximab IV at set times.
• Maximum dose / adjustments: Adjust to drug levels and renal function; many interactions.

Safety

• Contraindications: Agent-specific; mycophenolate in pregnancy.
• Black box warning: Class warnings for increased risk of serious infections and malignancy (especially lymphoma and skin cancer), and that these should be managed by experienced specialists; cyclosporine and tacrolimus add nephrotoxicity; mycophenolate adds embryo-fetal toxicity (pregnancy loss and malformations); azathioprine adds malignancy and mutagenicity (TPMT testing guides dosing).
• Interactions: Many CYP3A4 interactions (azole antifungals, macrolides, grapefruit juice raise levels), other nephrotoxic drugs, live vaccines (avoid), allopurinol with azathioprine (severe toxicity).
• Pregnancy / lactation: Mycophenolate contraindicated; others under specialist care.
• High-alert: No.

Adverse effects

• Common side effects: Tremor, hypertension, GI upset, gum overgrowth and hirsutism (cyclosporine), tremor and glucose elevation (tacrolimus), GI effects (mycophenolate).
• Serious effects to report: Serious infection, nephrotoxicity, new malignancy, neurotoxicity, marrow suppression.
• Antidote / reversal: Supportive care; hold and adjust.

Nursing process

• Assessment before administration: Drug trough level, renal function, blood pressure, infection signs, CBC, TPMT (azathioprine), pregnancy status (mycophenolate).
• Interventions during therapy: Draw troughs correctly (timing matters); avoid grapefruit; protect skin from sun (cancer risk); avoid live vaccines; stress adherence.
• Monitor: Trough levels, renal function, blood pressure, CBC, glucose, infection and malignancy surveillance.
• Evaluation / expected outcome: Graft survival or autoimmune control without toxicity.

Patient teaching

• Patient teaching: Take exactly as prescribed and never miss doses (rejection risk); avoid grapefruit; use sun protection; report infection; reliable contraception (mycophenolate).
• Notify provider if: Fever or infection, decreased urination, new skin lesions, tremor or confusion.
• Administration tips: Consistent timing and formulation; trough monitoring; avoid grapefruit.